Volume 27, Number 1—January 2021
Research
Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines
Shalom Ben-Shimol, Noga Givon-Lavi, Leore Kotler, Bart Adriaan van der Beek, David Greenberg, and Ron Dagan
Table 3
Antimicrobial nonsusceptibility among pneumococcal isolates in children age <24 mo, Israel, 2015–2017*
| Drug and MIC | Carriage in healthy children |
Carriage in non-LRTI |
Carriage in LRTI |
Conjunctivitis |
Otitis media |
IPD |
All outcomes |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VT20-13, n = 261 | NVT20, n = 706 | p value | VT20–13, n = 150 | NVT20, n = 433 | p value | VT20–13, n = 141 | NVT20, n = 253 | p value | VT2–13, n = 20 | NVT20, n = 75 | p value | VT2–13, n = 26 | NVT20, n = 40 | p value | VT20–13, n = 112 | NVT20, n = 82 | p value | VT20–13, n = 710 | NVT20, n = 1,589 | p value | |||||||
| Penicillin >0.1 | 49 | 55 | 0.08 | 43 | 45 | 0.7 | 46 | 50 | 0.53 | 35 | 41 | 0.8 | 38 | 35 | 0.8 | 30 | 13 | 0.006 | 43 | 48 | 0.03 | ||||||
| Penicillin >1.0 | 3 | 18 | <0.001 | 5 | 17 | <0.001 | 7 | 14 | 0.03 | 0 | 13 | 0.11 | 0 | 3 | 1.0 | 0 | 1 | 0.42 | 4 | 16 | <0.001 | ||||||
| Ceftriaxone >1.0 | 0 | 0 | 1.0 | 1 | 0 | 0.26 | 0 | 0 | 1.0 | 0 | 0 | 1.0 | 0 | 3 | 1.0 | 0 | 0 | 1.0 | 0 | 0 | 1.0 | ||||||
| Erythromycin >21 | 31 | 15 | <0.001 | 31 | 15 | <0.001 | 28 | 19 | 0.03 | 30 | 16 | 0.2 | 19 | 5 | 0.1 | 8 | 9 | 1.0 | 26 | 15 | <0.001 | ||||||
| Tetracycline >23 | 31 | 18 | <0.001 | 31 | 19 | 0.004 | 27 | 21 | 0.21 | 40 | 12 | 0.007 | 12 | 10 | 1.0 | 6 | 16 | 0.03 | 26 | 18 | <0.001 | ||||||
| Chloramphenicol >20 | 2 | 0 | 0.09 | 1 | 0 | 0.27 | 1 | 2 | 0.66 | 0 | 4 | 1.0 | 4 | 0 | 0.39 | 1 | 0 | 1.0 | 1 | 1 | 1.0 | ||||||
| SXT >19 | 51 | 49 | 0.66 | 63 | 48 | 0.002 | 49 | 49 | 1.0 | 40 | 28 | 0.41 | 27 | 13 | 0.19 | 45 | 33 | 0.11 | 51 | 46 | 0.04 | ||||||
| Clindamycin >19 | 19 | 7 | <0.001 | 27 | 9 | <0.001 | 24 | 7 | <0.001 | 30 | 12 | 0.08 | 19 | 5 | 0.1 | 8 | 7 | 1.0 | 20 | 7 | <0.001 | ||||||
| MDR | 32 | 19 | <0.001 | 31 | 17 | <0.001 | 27 | 21 | 0.22 | 35 | 13% | 0.04 | 19 | 5 | 0.1 | 7 | 9 | 0.79 | 26 | 18 | <0.001 | ||||||
*Values are percentage of total pneumococcal isolates except as indicated. IPD, invasive pneumococcal disease; LRTI, lower respiratory tract infection; MDR, multidrug resistance; NVT20, serotypes not included in PCV20; SXT, trimethoprim/sulfamethoxazole; VT20–13, additional 20-valent PCV (PCV20) serotypes, not included in 13-valent pneumococcal conjugate vaccine (PCV13).
Page created: November 19, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.